Tebanicline

Research use only, not for human use.

Tebanicline (ABT-594, Ebanicline) acts as a partial agonist at neuronal nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes.

Tebanicline (ABT-594, Ebanicline) acts as a partial agonist at neuronal nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes. Tebanicline is an effective synthetic nicotinic (non-opioid) analgesic drug developed by Abbott. It was developed as a less toxic analog of the potent poison dart frog-derived compound epibatidine, which is some 200x stronger than morphine as an analgesic but produces extremely dangerous toxic side effects. Like epibatidine, Tebanicline showed potent analgesic activity against neuropathic pain in both animal and human trials, but with far less toxicity than its parent compound.

——

——

——

Cell Cycle/DNA Damage

PLK

nAChR

——

——

198283-73-7

198.65

C9H11ClN2O

>98% (HPLC)

——

C1CN[C@H]1COc1cnc(cc1)Cl

——

(-20℃)

With Ice Pack

≥ 2 years